Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 169 to 175 of 175 entries
Sorted by: Best Match Show Resources per page
Targeted Sub-Attomole Cancer Biomarker Detection Based on Phase Singularity 2D Nanomaterial-Enhanced Plasmonic Biosensor.

Nano-micro letters

Wang Y, Zeng S, Crunteanu A, Xie Z, Humbert G, Ma L, Wei Y, Brunel A, Bessette B, Orlianges JC, Lalloué F, Schmidt OG, Yu N, Ho HP.
PMID: 34138312
Nanomicro Lett. 2021 Mar 22;13(1):96. doi: 10.1007/s40820-021-00613-7.

HIGHLIGHTS: A zero-reflection-induced phase singularity is achieved through precisely controlling the resonance characteristics using two-dimensional nanomaterials. An atomically thin nano-layer having a high absorption coefficient is exploited to enhance the zero-reflection dip, which has led to the subsequent phase...

Cite
Wang Y, Zeng S, Crunteanu A, et al. Targeted Sub-Attomole Cancer Biomarker Detection Based on Phase Singularity 2D Nanomaterial-Enhanced Plasmonic Biosensor. Nanomicro Lett. 2021;13(1):96doi: 10.1007/s40820-021-00613-7.
Wang, Y., Zeng, S., Crunteanu, A., Xie, Z., Humbert, G., Ma, L., Wei, Y., Brunel, A., Bessette, B., Orlianges, J. C., Lalloué, F., Schmidt, O. G., Yu, N., & Ho, H. P. (2021). Targeted Sub-Attomole Cancer Biomarker Detection Based on Phase Singularity 2D Nanomaterial-Enhanced Plasmonic Biosensor. Nano-micro letters, 13(1), 96. https://doi.org/10.1007/s40820-021-00613-7
Wang, Yuye, et al. "Targeted Sub-Attomole Cancer Biomarker Detection Based on Phase Singularity 2D Nanomaterial-Enhanced Plasmonic Biosensor." Nano-micro letters vol. 13,1 (2021): 96. doi: https://doi.org/10.1007/s40820-021-00613-7
Wang Y, Zeng S, Crunteanu A, Xie Z, Humbert G, Ma L, Wei Y, Brunel A, Bessette B, Orlianges JC, Lalloué F, Schmidt OG, Yu N, Ho HP. Targeted Sub-Attomole Cancer Biomarker Detection Based on Phase Singularity 2D Nanomaterial-Enhanced Plasmonic Biosensor. Nanomicro Lett. 2021 Mar 22;13(1):96. doi: 10.1007/s40820-021-00613-7. PMID: 34138312; PMCID: PMC7985234.
Copy Download .nbib Format: NLM
Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice.

Translational oncology

Ishiguro S, Upreti D, Bassette M, Singam ERA, Thakkar R, Loyd M, Inui M, Comer J, Tamura M.
PMID: 34990908
Transl Oncol. 2022 Feb;16:101337. doi: 10.1016/j.tranon.2021.101337. Epub 2022 Jan 03.

A novel peptide that interferes with the PD-1/PD-L1 immune checkpoint pathway, termed PD-L1 inhibitory peptide 3 (PD-L1ip3), was computationally designed, experimentally validated for its specific binding to PD-L1, and evaluated for its antitumor effects in cell culture and in...

Cite
Ishiguro S, Upreti D, Bassette M, et al. Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice. Transl Oncol. 2022;16:101337doi: 10.1016/j.tranon.2021.101337.
Ishiguro, S., Upreti, D., Bassette, M., Singam, E. R. A., Thakkar, R., Loyd, M., Inui, M., Comer, J., & Tamura, M. (2022). Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice. Translational oncology, 16101337. https://doi.org/10.1016/j.tranon.2021.101337
Ishiguro, Susumu, et al. "Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice." Translational oncology vol. 16 (2022): 101337. doi: https://doi.org/10.1016/j.tranon.2021.101337
Ishiguro S, Upreti D, Bassette M, Singam ERA, Thakkar R, Loyd M, Inui M, Comer J, Tamura M. Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice. Transl Oncol. 2022 Feb;16:101337. doi: 10.1016/j.tranon.2021.101337. Epub 2022 Jan 03. PMID: 34990908.
Copy Download .nbib Format: NLM
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.

Circulation

Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, Bessette LG, Lee H, Garry EM, Gautam N, Schneeweiss S.
PMID: 33327727
Circulation. 2021 Mar 09;143(10):1002-1013. doi: 10.1161/CIRCULATIONAHA.120.051718. Epub 2020 Dec 17.

BACKGROUND: Regulators are evaluating the use of noninterventional real-world evidence (RWE) studies to assess the effectiveness of medical products. The RCT DUPLICATE initiative (Randomized, Controlled Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology) uses a structured...

Cite
Franklin JM, Patorno E, Desai RJ, et al. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2020;143(10):1002-1013doi: 10.1161/CIRCULATIONAHA.120.051718.
Franklin, J. M., Patorno, E., Desai, R. J., Glynn, R. J., Martin, D., Quinto, K., Pawar, A., Bessette, L. G., Lee, H., Garry, E. M., Gautam, N., & Schneeweiss, S. (2021). Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation, 143(10), 1002-1013. https://doi.org/10.1161/CIRCULATIONAHA.120.051718
Franklin, Jessica M, et al. "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative." Circulation vol. 143,10 (2021): 1002-1013. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.051718
Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, Bessette LG, Lee H, Garry EM, Gautam N, Schneeweiss S. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021 Mar 09;143(10):1002-1013. doi: 10.1161/CIRCULATIONAHA.120.051718. Epub 2020 Dec 17. PMID: 33327727; PMCID: PMC7940583.
Copy Download .nbib Format: NLM
Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice.

Translational oncology

Ishiguro S, Upreti D, Bassette M, Singam ERA, Thakkar R, Loyd M, Inui M, Comer J, Tamura M.
PMID: 34990908
Transl Oncol. 2022 Feb;16:101337. doi: 10.1016/j.tranon.2021.101337. Epub 2022 Jan 03.

A novel peptide that interferes with the PD-1/PD-L1 immune checkpoint pathway, termed PD-L1 inhibitory peptide 3 (PD-L1ip3), was computationally designed, experimentally validated for its specific binding to PD-L1, and evaluated for its antitumor effects in cell culture and in...

Cite
Ishiguro S, Upreti D, Bassette M, et al. Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice. Transl Oncol. 2022;16:101337doi: 10.1016/j.tranon.2021.101337.
Ishiguro, S., Upreti, D., Bassette, M., Singam, E. R. A., Thakkar, R., Loyd, M., Inui, M., Comer, J., & Tamura, M. (2022). Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice. Translational oncology, 16101337. https://doi.org/10.1016/j.tranon.2021.101337
Ishiguro, Susumu, et al. "Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice." Translational oncology vol. 16 (2022): 101337. doi: https://doi.org/10.1016/j.tranon.2021.101337
Ishiguro S, Upreti D, Bassette M, Singam ERA, Thakkar R, Loyd M, Inui M, Comer J, Tamura M. Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice. Transl Oncol. 2022 Feb;16:101337. doi: 10.1016/j.tranon.2021.101337. Epub 2022 Jan 03. PMID: 34990908; PMCID: PMC8741604.
Copy Download .nbib Format: NLM
Using Network Parcels and Resting-State Networks to Estimate Correlates of Mood Disorder and Related Research Domain Criteria Constructs of Reward Responsiveness and Inhibitory Control.

Biological psychiatry. Cognitive neuroscience and neuroimaging

Langenecker SA, Westlund Schreiner M, Thomas LR, Bessette KL, DelDonno SR, Jenkins LM, Easter RE, Stange JP, Pocius SL, Dillahunt A, Love TM, Phan KL, Koppelmans V, Paulus M, Lindquist MA, Caffo B, Mickey BJ, Welsh RC.
PMID: 34271215
Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jul 13; doi: 10.1016/j.bpsc.2021.06.014. Epub 2021 Jul 13.

BACKGROUND: Resting-state graph-based network edges can be powerful tools for identification of mood disorders. We address whether these edges can be integrated with Research Domain Criteria (RDoC) constructs for accurate identification of mood disorder-related markers, while minimizing active symptoms...

Cite
Langenecker SA, Westlund Schreiner M, Thomas LR, et al. Using Network Parcels and Resting-State Networks to Estimate Correlates of Mood Disorder and Related Research Domain Criteria Constructs of Reward Responsiveness and Inhibitory Control. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;doi: 10.1016/j.bpsc.2021.06.014.
Langenecker, S. A., Westlund Schreiner, M., Thomas, L. R., Bessette, K. L., DelDonno, S. R., Jenkins, L. M., Easter, R. E., Stange, J. P., Pocius, S. L., Dillahunt, A., Love, T. M., Phan, K. L., Koppelmans, V., Paulus, M., Lindquist, M. A., Caffo, B., Mickey, B. J., & Welsh, R. C. (2021). Using Network Parcels and Resting-State Networks to Estimate Correlates of Mood Disorder and Related Research Domain Criteria Constructs of Reward Responsiveness and Inhibitory Control. Biological psychiatry. Cognitive neuroscience and neuroimaging, . https://doi.org/10.1016/j.bpsc.2021.06.014
Langenecker, Scott A, et al. "Using Network Parcels and Resting-State Networks to Estimate Correlates of Mood Disorder and Related Research Domain Criteria Constructs of Reward Responsiveness and Inhibitory Control." Biological psychiatry. Cognitive neuroscience and neuroimaging vol. (2021). doi: https://doi.org/10.1016/j.bpsc.2021.06.014
Langenecker SA, Westlund Schreiner M, Thomas LR, Bessette KL, DelDonno SR, Jenkins LM, Easter RE, Stange JP, Pocius SL, Dillahunt A, Love TM, Phan KL, Koppelmans V, Paulus M, Lindquist MA, Caffo B, Mickey BJ, Welsh RC. Using Network Parcels and Resting-State Networks to Estimate Correlates of Mood Disorder and Related Research Domain Criteria Constructs of Reward Responsiveness and Inhibitory Control. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jul 13; doi: 10.1016/j.bpsc.2021.06.014. Epub 2021 Jul 13. PMID: 34271215.
Copy Download .nbib Format: NLM
BDNF and pro-BDNF in serum and exosomes in major depression: Evolution after antidepressant treatment.

Progress in neuro-psychopharmacology & biological psychiatry

Gelle T, Samey RA, Plansont B, Bessette B, Jauberteau-Marchan MO, Lalloué F, Girard M.
PMID: 33358963
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110229. doi: 10.1016/j.pnpbp.2020.110229. Epub 2020 Dec 31.

BACKGROUND: The study of clinically related biological indicators in Major Depression (MD) is important. The Brain Derived Neurotrophic Factor (BDNF) appears to play an important role in MD, through its neurotrophic effect, and its levels are significantly decreased. The...

Cite
Gelle T, Samey RA, Plansont B, et al. BDNF and pro-BDNF in serum and exosomes in major depression: Evolution after antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2020;109:110229doi: 10.1016/j.pnpbp.2020.110229.
Gelle, T., Samey, R. A., Plansont, B., Bessette, B., Jauberteau-Marchan, M. O., Lalloué, F., & Girard, M. (2021). BDNF and pro-BDNF in serum and exosomes in major depression: Evolution after antidepressant treatment. Progress in neuro-psychopharmacology & biological psychiatry, 109110229. https://doi.org/10.1016/j.pnpbp.2020.110229
Gelle, Thibaut, et al. "BDNF and pro-BDNF in serum and exosomes in major depression: Evolution after antidepressant treatment." Progress in neuro-psychopharmacology & biological psychiatry vol. 109 (2021): 110229. doi: https://doi.org/10.1016/j.pnpbp.2020.110229
Gelle T, Samey RA, Plansont B, Bessette B, Jauberteau-Marchan MO, Lalloué F, Girard M. BDNF and pro-BDNF in serum and exosomes in major depression: Evolution after antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110229. doi: 10.1016/j.pnpbp.2020.110229. Epub 2020 Dec 31. PMID: 33358963.
Copy Download .nbib Format: NLM
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.

Circulation

Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, Bessette LG, Lee H, Garry EM, Gautam N, Schneeweiss S.
PMID: 33327727
Circulation. 2021 Mar 09;143(10):1002-1013. doi: 10.1161/CIRCULATIONAHA.120.051718. Epub 2020 Dec 17.

BACKGROUND: Regulators are evaluating the use of noninterventional real-world evidence (RWE) studies to assess the effectiveness of medical products. The RCT DUPLICATE initiative (Randomized, Controlled Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology) uses a structured...

Cite
Franklin JM, Patorno E, Desai RJ, et al. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2020;143(10):1002-1013doi: 10.1161/CIRCULATIONAHA.120.051718.
Franklin, J. M., Patorno, E., Desai, R. J., Glynn, R. J., Martin, D., Quinto, K., Pawar, A., Bessette, L. G., Lee, H., Garry, E. M., Gautam, N., & Schneeweiss, S. (2021). Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation, 143(10), 1002-1013. https://doi.org/10.1161/CIRCULATIONAHA.120.051718
Franklin, Jessica M, et al. "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative." Circulation vol. 143,10 (2021): 1002-1013. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.051718
Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, Pawar A, Bessette LG, Lee H, Garry EM, Gautam N, Schneeweiss S. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021 Mar 09;143(10):1002-1013. doi: 10.1161/CIRCULATIONAHA.120.051718. Epub 2020 Dec 17. PMID: 33327727; PMCID: PMC7940583.
Copy Download .nbib Format: NLM
Showing 169 to 175 of 175 entries